Read Simon

Read Simon is listed in filings as Director at Dianthus Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 22, 2026, including 2 public disclosures. Recent filings connect the profile to Dianthus Therapeutics, Inc. (DNTH). The current snapshot covers public activity from May 22, 2025 to May 22, 2026. Reported amounts are shown as $545.8K to $459.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.